Cobenfy is the first schizophrenia drug in decades to treat the mental health condition in a new way, with potentially fewer ...

The retrospective study presented at ESMO 2024 involved about 2,400 patients with stage 3 or 4 non-small cell lung cancer.

Prime Medicine and Bristol Myers Squibb are collaborating on next-generation ex vivo T-cell therapies. Read more here.

On Friday, Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $50.91 which represents a slight increase of $0.79 or 1.58% from the prior close of $50.12. The stock opened at ...

MM+M’s 2024 Healthcare Marketers Trend Report reveals that AI and tech are top of mind for healthcare marketers. In this recent #TrendTalks session titled “The Ideal Customer Experience Across the ...

After putting on a strong performance in preventing disease progression in the earlier treatment of multiple myeloma, Johnson ...

RA Capital, RTW Investments, Janus Henderson Investors are pouring another $175 million into a radiopharmaceuticals startup.

Prime Medicine said it will receive a $55 million upfront payment and a $55 million investment from Bristol Myers Squibb. It will is also eligible to receive more than $3.5 billion in milestones, ...

Prime Medicine enters a strategic collaboration with Bristol Myers Squibb to develop next-gen T-cell therapies, securing $110 million upfront with potential for $3.5 billion in milestones. The company ...

Prime Medicine, Inc. (PRME) announced Monday a strategic research collaboration and license agreement with Bristol Myers Squibb (BMY) ...

In a 3-year extension of the pivotal trials that provided lebrikizumab with an indication for atopic dermatitis, the response ...